Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

ConclusionsOnce-daily seviteronel was generally well tolerated in women with and 450  mg QD was chosen as the RP2D.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research